A Phase 2, Double-blind Dose Escalation Regimen of Once-Weekly OPK-88003 in Subjects With Type 2 Diabetes
Phase of Trial: Phase II
Latest Information Update: 16 Apr 2018
At a glance
- Drugs Pegapamodutide (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Sponsors OPKO Health
- 23 Mar 2018 According to the OPKO Health media release, first patient has been enrolled in this study.
- 23 Mar 2018 Status changed from not yet recruiting to recruiting, according to the OPKO Health media release.
- 16 Aug 2017 New trial record